Pubblicazione scientifica

Liquiritigenin Reduces Blood Glucose Level and Bone Adverse Effects in Hyperglycemic Adult Zebrafish

FILONE TECNOLOGICO	TEMA
trasformazione e commercializzazione	macchinari di ausilio alla lavorazione e trasformazione del pesce

RIASSUNTO

Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia that induces other pathologies including diabetic retinopathy and bone disease. Adult Danio rerio (zebrafish) represents a powerful model to study both glucose and bone metabolism. Then, the aim of this study was to evaluate the effects of liquiritigenin (LTG) on blood glucose level and diabetes complications in hyperglycemic adult zebrafish. LTG is a flavonoid extracted from Glycyrrhiza glabra roots which possess important antioxidant, anti-inflammatory, and anti-diabetic properties. During four weeks of glucose treatment, LTG significantly prevented the onset of the hyperglycemia in adult zebrafish. Moreover, hyperglycemic fish showed increased advanced glycation end-products (AGEs) and parathormone levels whereas LTG completely prevented both of these metabolic alterations. Large bone-loss areas were found in the scales of glucose-treated fish whereas only small resorption lacunae were detected after glucose/LTG treatment. Biochemical and histological tartrate resistant acid phosphatase (TRAP) assays performed on explanted scales confirmed that LTG prevented the increase of osteoclastic activity in hyperglycemic fish. The osteoblastic alkaline phosphatase (ALP) activity was clearly lost in scales of glucose-treated fish whereas the co-treatment with LTG completely prevented such alteration. Gene expression analysis showed that LTG prevents the alteration in crucial bone regulatory genes. Our study confirmed that LTG is a very promising natural therapeutic approach for blood glucose lowering and to contrast the development of bone complications correlated to chronic hyperglycemia.

DATA

Data di pubblicazione: 09/05/2019

AUTORI

CARNOVALI MARTA
LUZI LIVIO
TERRUZZI ILEANA
BANFI GIUSEPPE
MARIOTTI MASSIMO

ENTE DI AFFERENZA

GRUPPO OSPEDALIERO SAN DONATO FNDN 20122 MILAN ITALY MARTA CARNOVALI GRUPPOSANDONATO IT
POLICLINICO SAN DONATO IRCCS 20097 MILAN ITALY LIVIO LUZI UNIMI IT
DEPT BIOMEDICAL SCIENCES FOR HEALTH UNIV MILAN 20133 MILAN ITALY
DIABETES RSCH INST METABOLISM NUTRIGENOMICS & CELLULAR DIFFERENTIATION UNIT SAN RAFFAELE SCIENTIFIC INST 20132 MILAN ITALY TERRUZZI ILEANA HSR IT
IRCCS ORTHOPEDIC INST GALEAZZI 20161 MILAN ITALY BANFI GIUSEPPE FONDAZIONESANRAFFAELE IT
FACULTY OF MEDICINE & SURGERY VITA SALUTE SAN RAFFAELE UNIV 20122 MILAN ITALY
DEPT BIOMEDICAL SURGICAL & DENTAL SCIENCES UNIV MILAN 20122 MILAN ITALY

RIVISTA

Nutrients, 11(5), 1042

IMPACT FACTOR

4,210

indietro